CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Chimeric Antigen Receptor Pioneer Sees Solid Tumor Potential

August 26th 2015

A Giant of Cancer Care anticipates that CAR therapy will be beneficial not only in hematologic cancers, where it has proved effective, but also in solid tumors.

CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL

April 24th 2015

The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Sadelain on CAR T-Cell Therapies

April 10th 2015

Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.

Dr. Brentjens on CAR T-Cell Therapy Challenges

January 30th 2015

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, talks about the challenges of Chimeric Antigen Receptor (CAR) T-Cell therapies for the treatment of hematologic cancers.

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL

December 16th 2014

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Bringing CARs to Market: Novel T-Cell Therapies Make Rapid Progress Despite Challenges

November 18th 2014

When Marcela V. Maus, MD, PhD, thinks of the challenge of bringing chimeric antigen receptor (CAR) therapies to market in the battle against cancer, she is reminded of the auto industry's first days.

CAR Therapy Demonstrates Promise in ALL

October 17th 2014

The investigational chimeric antigen receptor (CAR) therapy CTL019 demonstrated promising activity in 2 pilot trials, eliciting complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL).

Rosenberg Sees New Milestone in Latest CAR Findings

September 9th 2014

Steven A. Rosenberg, MD, PhD, discusses the implications of responses to the CAR T-cell therapy KTE-C19, particularly among patients with chemotherapy-refractory diffuse large B-cell lymphomas.

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond

August 29th 2014

Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.

First CAR Therapy Receives FDA Breakthrough Designation

July 8th 2014

The investigational CD19-targeted CAR therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory ALL.